Posted on

AIkido Pharma Announces Third Quarter Highlights and Corporate Update

AIkido Pharma Announces Third Quarter Highlights and Corporate Update

Highlights recent investments in Electric Vehicles, Cannabis, Tele-health & Innovative Sports Businesses with near term monetization and liquidity events forthcoming

NEW YORK , Nov. 11, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced its third quarter ending September 30, 2021 , financial highlights and provided a corporate update.

 

Highlights

  • Cash and investments exceeding $104 million reflecting very low cash burn over Q2
  • Monetization and liquidity event in DatChat representing over 600% ROI
  • Investment in Tevva Motors electric truck producer, a space with recent Rivian Automotive IPO, ticker symbol RIVN.
  • Investment in Kerna Health, fast growth tele-health business with recurring revenue and large contract backlog with possible liquidity event in 2022
  • New investment in Slinger Bag, displaying strong progress and potential near-term monetization
  • New investment in Kaya Holding Corporation, a technology company focused on the development of “High There” the world’s largest cannabis social network and the launch of the world’s first cannabis media exchange.  Since the Company’s investment, the valuation of Kaya has more than doubled.

Anthony Hayes , CEO of AIkido, noted, “We are excited about our current pipeline portfolio, upcoming milestones and pending catalysts. This past quarter showcased our monetization strategy exemplified by a 600% ROI liquidity event in DatChat which went public over the summer. Additionally, we actively invested in several exciting high growth industries such as Electric Vehicles and Tele-health and we continue to actively pursue additional high growth interests with near term monetization events to help enhance shareholder value. We are pleased to also announce today our recent investments in the Cannabis and innovative sports industries that have strong growth potential. We are also working diligently to grow our drug platform through additional licensing efforts and are currently working on partnerships with academic institutions and private enterprise to find, fund and advance new drug compounds that can be brought to commercialization. We continue to maintain an extremely low cash burn and note that our valuation does not currently reflect the value of our assets. With our strong balance sheet, we have pulled our registration statement and we look forward to continued shareholder value creation.”

Third Quarter Highlights

DatChat
On August 17, 2021 , DatChat closed its initial public offering at an initial offering price to the public of $4.15 per share under the ticker DATS. On September 22, 2021 , the Company sold 167,084 shares of DatChat common stock for net proceeds of approximately $0.9 million . As of September 30, 2021 , the Company continued to hold 357,916 shares of DatChat valued at approximately $4.9 million .

Tevva Motors
On September 22, 2021 , the Company agreed to purchase 29,004 Interests of Tevva Motors for approximately $1.0 million . Subsequently, on September 30, 2021 , the Company entered into a second securities purchase agreement to purchase an additional 29,004 Interests of Tevva Motors for approximately $1.0 million . Tevva Motors Ltd is a UK-based, leading developer of modular electrification systems for medium duty commercial vehicles. This is an exciting space, with companies such as Rivian Automotive recently going public with very high valuations.

Kerna Health,
On September 15, 2021 , the Company entered into a securities purchase agreement with Kerna Health Inc. Under Agreement, the Company agreed to purchase 1,333,334 shares of common stock of Kerna for $1.0 million . Kerna health is a fast-growing tele-health business with recurring revenue and large contract backlog and has the potential to lead to a liquidity event in 2022.

Slinger Bag
On August 6, 2021 , the Company entered into a securities purchase agreement with Slinger Bag Inc. Under the Agreement, the Company agreed to pay $1.4 million to Slinger Bag for the issuance of a convertible promissory note in the principal amount of $1.4 million and a common stock purchase warrant. Slinger Bag which is currently listed on the OTC market under symbol SLBG, is a fast-growing leading connected sports company focused on delivering innovative, game improvement technologies and equipment across tennis and other ball sports.

Kaya Holding Corp
The Company on September 29 th entered into a securities purchase agreement with Kaya Holding Corporation.  Under the agreement, the Company agreed to purchase 8,325,000 shares of common stock of Kaya for $0.70 million .  Kaya is a technology company focused on the development of “High There” the world’s largest cannabis social network and the launch of the world’s first cannabis media exchange.  Since the Company’s investment, the valuation of Kaya has more than doubled.  The Kaya app is available for download for both Apple and Android phones.

Drug Development Pipeline Update
The Company’s pipeline consists of patented technology from leading universities and researchers and is currently in the process of developing its innovative therapeutic drug pipeline through strong partnerships with world renowned educational institutions, including the University of Texas at Austin , the University of Maryland, Baltimore and Wake Forest University .

  • The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.

Convergent Therapeutics
In January 2021 , the Company invested in Convergent Therapeutics, which has exclusive rights to technology related to next-generation dual-action peptide receptor radionuclide therapy (“PRRT”) for prostate cancer covered by multiple issued U.S. and foreign patents. Convergent is currently conducting advanced human trials relating to prostate cancer treatments utilizing PRRT that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells. The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

Silo Pharma
In January 2021 , the Company entered into an exclusive patent license agreement with Silo Pharma where Silo Pharma granted the Company a worldwide exclusive, sublicensable, royalty-bearing license to certain Silo Pharma owned provisional patent applications directed to the use of psilocybin in cancer treatment. The license is for “Field of Use” of “treatment of cancer and symptoms caused by cancer, including but not limited to pain, nausea, neuroinflammation, brain and neural dysfunction, depression, seizures, confusion, dizziness, numbness/tingling, dysfunction of the senses and all other symptoms that are caused by cancer of any type.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

CisionView original content to download multimedia: https://www.prnewswire.com/news-releases/aikido-pharma-announces-third-quarter-highlights-and-corporate-update-301422204.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

Silo Pharma Reports Third Quarter Results and Operating Highlights

Silo Pharma Reports Third Quarter Results and Operating Highlights

Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today reported its financial results for the third quarter 2021 and gave an update on recent progress in its business.

Operating Highlights

  • Entered sponsored research agreement with Columbia University to develop psychedelic therapeutics for Alzheimer’s Disease and received an option to license assets currently under development
  • UMB awarded notice of allowance from the U.S. Patent and Trademark Office for central nervous system homing peptide patent on Silo’s licensed technology
  • Zylo Therapeutics and Silo Pharma’s joint venture received DEA Approval to advance the Patented Z-Pod technology to deliver ketamine
  • Advancement of sponsored research and option agreement with The University of Maryland, Baltimore for novel joint homing peptide for rheumatoid arthritis
  • Advancing with up-listing plan to the Nasdaq Stock Market
  • Total working capital approximately $11.0 million

Mr. Eric Weisblum, Chief Executive Officer of Silo Pharma, commented, “We are making progress in our efforts to advance research in psychedelics as a therapeutic and achieved several key milestones in the third quarter of 2021. We materially strengthened our balance sheet to advance our platform and accelerate our development plans. Additionally, we remain focused on our goal to uplist our shares to the Nasdaq, and believe the uplisting will strengthen long term shareholder value and serve as a catalyst to further diversify our shareholder base.”

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com

Posted on

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

  • Delivering psilocybin via microneedle patch unlocks potential for desired dosage forms and pharmacokinetic profiles for improved safety and effectiveness.
  • Completing microneedle patch research programs with other psychedelics before year-end.
  • Pursuing Phase 2 clinical studies in 2022 with psilocybin and notable psychedelics.

TORONTO, November 11, 2021 — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has successfully completed its first research study evaluating MicroDose-MN™, a proprietary microneedle (“MN”) patch for the intradermal delivery of psychedelics, in delivering psilocybin. These results provide support to file for an IND application with the FDA to conduct Phase 2 clinical studies in 2022 with psilocybin for various indications.

The aim of PharmaTher’s research program was to develop a suitable prototype of MicroDose-MN™ patch for transdermal (intradermal) drug delivery to confirm compatibility and suitability to deliver psilocybin. The research program scope included, full characterization of psilocybin conjugated on the microneedle patch backbone, establishment and demonstration of the loading capacity for psilocybin, and release rate evaluations for the psilocybin conjugated materials using appropriate models that will be used to support the Company’s IND application with the FDA.

The Company’s research program with psilocybin conjugated microneedles have been successfully fabricated, optimized, and characterized. Both structural aspects and ex-vivo skin insertion assessments of the psilocybin conjugated microneedles have demonstrated successful fabrication and acceptable performance. The incorporation of psilocybin per microneedle without issue and the ability to demonstrate complete ex vivo skin model release over several days demonstrates potential for larger doses and modified release profiles. With these results, the Company believes it has an acceptable prototype for completing IND-enabling studies with the aim to conduct clinical studies in 2022. Details of the research program will be published in a scientific journal.

The Company previously announced that it has entered into a collaboration agreement with Revive Therapeutics Ltd. (“Revive”) (OTCQB: RVVTF) (CSE: RVV) for the evaluation of the psilocybin MicroDose-MN™ patch and is currently in discussions with Revive in finalizing a definitive agreement to advance the clinical and commercial development. There can be no assurance that a definitive agreement will be entered into between PharmaTher and Revive.

The Company believes that its MicroDose-MN™ patch for delivering psilocybin and other psychedelics may enable flexible drug load capacity and combinations, controlled released delivery, and be able to present desired pharmacokinetic and safety profiles. In addition, the MicroDose-MN™ patch for psychedelics aims to empower patients to dose their medication remotely, safely and conveniently rather than under supervision by a healthcare provider at a certified medical office or hospital. To achieve this, the Company will incorporate anti-tampering and anti-abuse features that would parallel the approach used for the tamper-resistant transdermal fentanyl patch.

The Company is completing its evaluation of MicroDose-MN™ with 3,4-methylenedioxy-methamphetamine (“MDMA”), lysergic acid diethylamide (“LSD”), and N, N-dimethyltryptamine (“DMT”) and expects to provide results before the end of this year and pursue clinical studies in 2022.

The Company is actively engaged in partnering discussions for the use of its microneedle patch system to deliver psychedelics including, but not limited to, MDMA, LSD, DMT, ibogaine and mescaline. As such, PharmaTher offers potential partners a differentiated and validated delivery system for psychedelics, desired pharmacokinetic profiles, intellectual property protection, cGMP microneedle patches for IND-enabling and clinical studies, and a clear clinical pathway towards clinical studies in 2022.

About PharmaTher Holdings Ltd.

​PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics, such as ketamine, to treat mental health, neurological and pain disorders. PharmaTher is currently advancing an FDA approved phase 2 clinical study with ketamine to treat Parkinson’s disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics and infectious disease treatments.
​
Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn.

For more business development opportunities or information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim”, “may” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of August 31, 2021 (“MD&A”), dated October 27, 2021, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Posted on

IntelGenx Reports Third Quarter 2021 Financial Results

IntelGenx Reports Third Quarter 2021 Financial Results

SAINT LAURENT, Quebec, Nov. 11, 2021 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) today reported financial results for the third quarter ended September 30, 2021. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

2021 Third Quarter Financial Summary:

  • Revenue was $593,000, compared to $510,000 in the 2020 third quarter.
  • Net comprehensive loss was $2.2 million, compared to $1.6 million in Q3-2020.
  • Adjusted EBITDA loss was $1.4 million, compared to $1.2 million in the 2020 third quarter.

Third Quarter and Recent Developments:

  • Resumed patient screening in the ongoing ‘BUENA’ Montelukast VersaFilm® Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) following Health Canada’s issuance of a No Objection Letter in response to the Company’s amended Clinical Trial Application.
  • Graduated to the Toronto Stock Exchange.
  • Announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), Aquestive Therapeutics, Inc. (NASDAQ:AQST), entered into a definitive license and supply agreement with an undisclosed leading men’s health company.
  • Announced that atai Life Sciences AG (“atai”) committed $6.0 million in future financial support to IntelGenx via amendments to the loan facility between the parties.
  • Announced that Exeltis Healthcare S.L., the Company’s commercialization partner in the European Union for RIZAPORT®, a unique treatment for acute migraines, launched the product in Spain.
  • Completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings Corp.’s (CSE:CANN) Canadian market launch of its “CB4 Control” branded product.
  • Closed a $2.1 million private placement of 8% convertible notes due July 31, 2025, which the Company intends to use to finance its BUENA trial of Montelukast in AD.
  • Increased the size of the Board of Directors from six to eight with the appointments of Srinivas (Srini) G. Rao, M.D., Ph.D. and Frank Stegert.

“The past few months have been a very productive and exciting period for IntelGenx, marked by the achievement of five major milestones,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “Our graduation to the TSX, Canada’s most senior exchange, came on the heels of our successful transition from a development-stage to a commercial-stage leader in pharmaceutical films as well as our transformational partnership with atai. We were also pleased to resume patient screening in our ongoing ‘BUENA’ Montelukast VersaFilm Phase 2a clinical trial in patients with mild to moderate AD. Having executed on many elements of our growth strategy this quarter, we look forward to continuing to advance our portfolio of innovative film products and product candidates.”

Financial Results:

Total revenues for the three-month period ended September 30, 2021 amounted to $593,000, an increase of $83,000, or 16%, compared to $510,000 for the three-month period ended September 30, 2020. The change is mainly attributable to increases in sales milestone revenues of $320,000, product revenues of $70,000, partially offset by a $308,000 decrease in revenues from licensing agreements.

Operating costs and expenses were $2.2 million for the third quarter of 2021, versus $1.9 million for the corresponding three-month period of 2020. The increase for the three-month period ended September 30, 2021 is mainly attributable to increases of $26,000 in R&D expense, $255,000 in manufacturing expenses, $37,000 in selling, general and administrative expenses, $17,000 in depreciation of tangible assets.

For the third quarter of 2021, the Company had an operating loss of $1.6 million, compared to an operating loss of $1.4 million for the comparable period of 2020.

Net comprehensive loss for the three-month period ended September 30, 2021 was $2.2 million, or $0.01 per basic and diluted share, compared to net comprehensive loss of $1.6 million, or $0.01 per basic and diluted share, for the comparable period of 2020.

As at September 30, 2021, the Company’s cash and short-term investments totalled $12.0 million.

Conference Call Details:

IntelGenx will host a conference call to discuss these third quarter 2021 financial results today at 4:30 p.m. ET. The dial-in number for the conference call is (888) 506-0058 (Canada and the United States) and (973) 528-0135 (International), access code 995615. The call will also be webcast live and archived on the Company’s website at www.intelgenx.com under “Webcasts” in the Investors section.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information and Statements
This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would,” and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading “Risk Factors” in IntelGenx’s annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

IntelGenx Technologies Corp.

Consolidated Balance Sheet
(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)
(Unaudited)

September 30, 2021 December 31, 2020
Assets
Current
Cash $ 6,019 $ 1,205
Short-term investments 6,013 1,038
Accounts receivable 1,162 260
Prepaid expenses 116 162
Investment tax credits receivable 407 635
Contract asset – 354
Security deposits 204 407
Inventories 68 244
Total current assets 13,989 4,305
Leasehold improvements and equipment, net 5,348 5,851
Security deposits 252 252
Operating lease right-of-use-asset 1,050 710
Total assets $ 20,639 $ 11,118
Liabilities
Current
Accounts payable and accrued liabilities 2,304 1,989
Current portion of long-term debt – 561
Current portion of operating lease liability 248 141
Current portion of finance lease liability 35 25
Deferred revenue 192 166
Convertible notes – 1,486
Convertible debentures 5,317 –
Total current liabilities 8,096 4,368
Long-term debt 2,500 171
Convertible notes 3,965 1,505
Convertible debentures – 5,461
Operating lease liability 691 482
Finance lease liability 92 84
Deferred income tax liability 82 –
Total liabilities 15,426 12,071
Contingencies
Subsequent event
Shareholders’ equity
Capital stock, common shares, $0.00001 par value; 450,000,000 shares authorized; 150,627,761 shares issued and outstanding (2020: 111,429,532 common shares) 1 1
Additional paid-in capital 61,589 48,453
Accumulated deficit (55,005) (48,551)
Accumulated other comprehensive loss (1,372) (856)
Total shareholders’ equity (deficit) 5,213 (953)
$ 20,639 $ 11,118

IntelGenx Technologies Corp.

Consolidated Statement of Comprehensive Loss
(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)
(Unaudited)

For the Three-Month Period
 For the Nine-Month Period
Ended September 30,
 Ended September 30,
2021 2020 2021 2020
Revenues $ 593 $ 510  $ 1,041 $ 754
Total revenues 593 510  1,041 754
Expenses
Research and development expense 874 848 1,910 2,300
Manufacturing expenses 499 244 1,598 1,042
Selling, general and administrative expense 662 625 2,419 2,167
Depreciation of tangible assets 199 182 589 536
Total expenses 2,234 1,899 6,516 6,045
Operating loss (1,641) (1,389) (5,475) (5,291)
Finance and interest income 1 3 152 405
Financing and interest expense (365) (274) (1,134) (881)
Net financing and interest income (expense) (364) (271) (982) (476)
Loss before income taxes (2,005) (1,660) (6,457) (5,767)
Deferred income tax 3 – 3 –
Net loss (2,002) (1,660) (6,454) (5,767)
Other comprehensive (loss) income
Foreign currency translation adjustment (175) 40 (518) (108)
Change in fair value 4 51 2 79
(171) 91 (516) (29)
Comprehensive loss $ (2,173) $ (1,569) $ (6,970) $ (5,796)
Basic and diluted weighted average number of shares outstanding 150,590,729 110,259,652 131,576,774 107,818,057
Basic and diluted loss per common share $ (0.01) $ (0.01) $ (0.05) $ (0.05)
Posted on

Meet Delic 2022 Happening November 5th & 6th

Meet Delic 2022 Happening November 5th & 6th

Inaugural Meet Delic Experience Sells Out, Becomes World’s Largest Psychedelic and Wellness Event

Organizers Announce New 2022 Dates and Ticket Options and Release Highlights from This Year’s Revolutionary Weekend

Vancouver, BC, November 11, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source), a leader in new medicines and treatments for a modern world, has announced the inaugural Meet Delic event that took place on November 6 and 7 sold out, making the psychedelic edutainment experience and business expo the largest in the world. More than 2,500 people visited AREA15 in Las Vegas, Nevada, to attend and experience two days of programs and activities, including 20 hours of talks, panels and discussions at the intersection of psychedelics, wellness, and business by over 60 thought leaders, medical professionals and wellness advocates.

“We’re incredibly humbled and unbelievably inspired by the number of people who came out to Meet Delic and joined the conversation on the power of psychedelics to heal and to remove the stigmas surrounding them,” said Jackee Stang, co-founder of Delic. “The world and our minds have evolved, and so should our medicines. We’re already looking forward to 2022 and how we can continue to show the world the latest in proven health and wellness benefits of psychedelics.”

Meet Delic 2022 will take place on November 5 and 6, 2022, in Las Vegas and advanced tickets can be purchased at Tixr.com.

Here are highlights from this year’s revolutionary weekend of thought-provoking discussions, panels and entertainment:

Lamar Odom, the former NBA star, spoke about his journey to beat addiction, heal PTSD and anxiety through the use of psychedelic medicines and shared a sneak peek of his film, Reborn, which also chronicles his journey, with the film’s director, Zappy Zapolin, in a fireside chat.
Duncan Trussell, comedian and podcaster, brought the house down with a live taping of the ‘Family Hour’ with author and podcaster Aubrey Marcus, Vince Kadlubek, founder of Meow Wolf, and actor Johnny Pemberton.
Guests heard from scholars such as Dr. Carl L. Hart, Ziff Professor at Columbia University and former chair of the Department of Psychology; Dr. Molly Maloof, a lecturer within the Wellness Department of the Medical School at Stanford University; and Dr. Dave Rabin, MD, PhD, co-founder of the Board of Medicine, a nonprofit organization of physicians and scientists establishing the first peer-reviewed, evidence-based clinical guidelines for the production and safe use of currently unregulated alternative medicines, including plant medicines.
Other keynotes included Ifetayo Harvey, Alyson Charles, Chris Ryan, PhD, and George Goldsmith & Ekaterina Malievskaia, M.D., of COMPASS Pathways.
In addition to panels and keynotes, businesses like the Balanced Veterans Network (BVN), a non-profit that creates a safe space for the education, advocacy, and empowerment of alternative therapies for veterans, were onsite showcasing their cutting edge light therapy technology to help treat mental health issues such as PTSD, anxiety, depression, and chronic pain.
Guests experienced high-energy and provocative dance performances by Little Miss Nasty, throbbing beats Mindchatter and DJ David Starfire, and stunning visual experiences by Sporeganic and VJ Jonathan Singer.
Ketamine Wellness Centers (KWC), a subsidiary of Delic Corp, set a record for incoming calls in 24 hours with nearly 2,000 logged during the weekend showing how Delic’s ecosystem concept of businesses really works.
Media Contacts:

Monica M. Jaramillo, LABEL The Agency, jaramillo@labeltheagency.com, 310.701.9714 & Shae Savin, shaesavinpr@gmail.com

###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp.

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Delic Holdings Corp

Posted on

Cybin to Present at the Jefferies London Healthcare Conference

Cybin to Present at the Jefferies London Healthcare Conference

TORONTO–(BUSINESS WIRE)– Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present virtually at the Jefferies London Healthcare Conference being held virtually November 18-19, 2021.

Mr. Drysdale’s presentation will be available on demand beginning on Thursday, November 18, 2021 at 8:00 a.m. GMT/3:00 a.m. ET through Friday, November 19, 2021 at 5:00pm GMT/12:00pm ET. To view the presentation, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Investor & Media:

Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com

Tim Regan/Scott Eckstein
KCSA Strategic Communications
cybin@kcsa.com

Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com

Source: Cybin Inc.

Posted on

AIkido Pharma Announces Third Quarter Highlights and Corporate Update

AIkido Pharma Announces Third Quarter Highlights and Corporate Update

Highlights recent investments in Electric Vehicles, Cannabis, Tele-health & Innovative Sports Businesses with near term monetization and liquidity events forthcoming

  • Cash and investments exceeding $104 million reflecting very low cash burn over Q2
  • Monetization and liquidity event in DatChat representing over 600% ROI
  • Investment in Tevva Motors electric truck producer, a space with recent Rivian Automotive IPO, ticker symbol RIVN.
  • Investment in Kerna Health, fast growth tele-health business with recurring revenue and large contract backlog with possible liquidity event in 2022
  • New investment in Slinger Bag, displaying strong progress and potential near-term monetization
  • New investment in Kaya Holdings, first U.S. publicly traded company to hold and operate state-issued “touch-the-plant” licenses for the retail, cultivation, and production of cannabis

Anthony Hayes , CEO of AIkido, noted, “We are excited about our current pipeline portfolio, upcoming milestones and pending catalysts. This past quarter showcased our monetization strategy exemplified by a 600% ROI liquidity event in DatChat which went public over the summer. Additionally, we actively invested in several exciting high growth industries such as Electric Vehicles and Tele-health and we continue to actively pursue additional high growth interests with near term monetization events to help enhance shareholder value. We are pleased to also announce today our recent investments in the Cannabis and innovative sports industries that have strong growth potential. We are also working diligently to grow our drug platform through additional licensing efforts and are currently working on partnerships with academic institutions and private enterprise to find, fund and advance new drug compounds that can be brought to commercialization. We continue to maintain an extremely low cash burn and note that our valuation does not currently reflect the value of our assets. With our strong balance sheet, we have pulled our registration statement and we look forward to continued shareholder value creation.”

Third Quarter Highlights

DatChat
On August 17, 2021 , DatChat closed its initial public offering at an initial offering price to the public of $4.15 per share under the ticker DATS. On September 22, 2021 , the Company sold 167,084 shares of DatChat common stock for net proceeds of approximately $0.9 million . As of September 30, 2021 , the Company continued to hold 357,916 shares of DatChat valued at approximately $4.9 million .

Tevva Motors
On September 22, 2021 , the Company agreed to purchase 29,004 Interests of Tevva Motors for approximately $1.0 million . Subsequently, on September 30, 2021 , the Company entered into a second securities purchase agreement to purchase an additional 29,004 Interests of Tevva Motors for approximately $1.0 million . Tevva Motors Ltd is a UK-based, leading developer of modular electrification systems for medium duty commercial vehicles. This is an exciting space, with companies such as Rivian Automotive recently going public with very high valuations.

Kerna Health,
On September 15, 2021 , the Company entered into a securities purchase agreement with Kerna Health Inc. Under Agreement, the Company agreed to purchase 1,333,334 shares of common stock of Kerna for $1.0 million . Kerna health is a fast-growing tele-health business with recurring revenue and large contract backlog and has the potential to lead to a liquidity event in 2022.

Slinger Bag
On August 6, 2021 , the Company entered into a securities purchase agreement with Slinger Bag Inc. Under the Agreement, the Company agreed to pay $1.4 million to Slinger Bag for the issuance of a convertible promissory note in the principal amount of $1.4 million and a common stock purchase warrant. Slinger Bag which is currently listed on the OTC market under symbol SLBG, is a fast-growing leading connected sports company focused on delivering innovative, game improvement technologies and equipment across tennis and other ball sports.

Kaya Holding Corp
On September 29, 2021 , the Company entered into a securities purchase agreement with Kaya Holding Corp. Under the Agreement, the Company agreed to purchase 8,325,000 shares of common stock of Kaya for approximately $0.7 million . Kaya Holding Corp is currently listed on the OTC market under the symbol KAYS and is the first U.S. publicly traded company to hold and operate state-issued “touch-the-plant” licenses for the retail, cultivation and production of cannabis.

Drug Development Pipeline Update
The Company’s pipeline consists of patented technology from leading universities and researchers and is currently in the process of developing its innovative therapeutic drug pipeline through strong partnerships with world renowned educational institutions, including the University of Texas at Austin , the University of Maryland, Baltimore and Wake Forest University .

The Company is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity in cell-based assays against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19.
Convergent Therapeutics
In January 2021 , the Company invested in Convergent Therapeutics, which has exclusive rights to technology related to next-generation dual-action peptide receptor radionuclide therapy (“PRRT”) for prostate cancer covered by multiple issued U.S. and foreign patents. Convergent is currently conducting advanced human trials relating to prostate cancer treatments utilizing PRRT that targets the prostate-specific membrane antigen (“PSMA”) present on prostate cancer cells. The technology was developed under the direction of Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine.

Silo Pharma
In January 2021 , the Company entered into an exclusive patent license agreement with Silo Pharma where Silo Pharma granted the Company a worldwide exclusive, sublicensable, royalty-bearing license to certain Silo Pharma owned provisional patent applications directed to the use of psilocybin in cancer treatment. The license is for “Field of Use” of “treatment of cancer and symptoms caused by cancer, including but not limited to pain, nausea, neuroinflammation, brain and neural dysfunction, depression, seizures, confusion, dizziness, numbness/tingling, dysfunction of the senses and all other symptoms that are caused by cancer of any type.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

CisionView original content to download multimedia: https://www.prnewswire.com/news-releases/aikido-pharma-announces-third-quarter-highlights-and-corporate-update-301422204.html

SOURCE AIkido Pharma Inc.

Posted on

Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium

Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium

November 10, 2021·3 min read

NEW YORK, Nov. 10, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present at the 4th Annual ALS ONE Research Symposium, November 29-30th, 2021.

Raj Mehra, Ph.D., Chairman and CEO will present as part of the industry updates on Tuesday, November 30th from 2:00-3:00pm ET to discuss SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS) which is the most recent regimen to be added on the HEALEY ALS Platform Trial.

The HEALEY ALS Platform Trial is designed to evaluate multiple investigational treatments simultaneously, thus accelerating the development of effective and breakthrough treatments for people living with ALS. Trehalose would be the fifth regimen in the Platform Trial. The Sean M. Healey & AMG Center for ALS works closely with the Northeast ALS Consortium (NEALS) and industry partners to tailor the Platform Trial arm to their experimental study drugs.

About ALS ONE

ALS ONE is a collaboration bringing together world-leading ALS researchers, doctors, and care practitioners focused on finding treatments for ALS and novel approaches to improve care and quality of life for individuals currently living with the disease. The unprecedented linking of minds and resources from Massachusetts General Hospital (MGH), University of Massachusetts Medical Center, ALS Therapy Development Institute (ALS TDI), and Compassionate Care ALS (CCALS) is unique for its leadership in efficiency, dedication to innovative research, and commitment to increasing access to care and treatment.

ALS ONE’s collaboration includes Dr. Merit Cudkowicz, MD, MSc, Chief of Neurology, Massachusetts General Hospital (MGH); Dr. Robert Brown Jr., MD, DPhil, Chief of Neurology, UMass Medical Center; Dr. James Berry, MD, Co-Director of the MGH Neuromuscular Division and of the MGH ALS Unit; Dr. Fernando Vieira, MD, Chief Executive Officer, ALS Therapy Development Institute; and Ron Hoffman, Founder and Director Compassionate Care ALS (CCALS).

Learn more about ALS ONE online at ALS ONE.org and for symposium information: https://2021alsoneresearchsymposium.splashthat.com/

About the Sean M. Healey & AMG Center

The Sean M. Healey & AMG Center at Massachusetts General Hospital, in collaboration with the Northeast ALS Consortium (NEALS), has launched the first ever platform trial for ALS. This project aims to greatly accelerate the timelines towards effective ALS treatments and to provide greater trial access for patients affected by this devastating disease.

The HEALEY ALS Platform Trial’s investigational new drug application (IND) was approved by the FDA in January 2020 and is a collaborative effort with the initial goal of 54 clinical trial sites prepared to enroll patients this year across the U.S. to provide greater access to patients wishing to participate.

For Healey ALS Platform Trial updates: https://www.massgeneral.org/neurology/als/research/platform-trial-news/

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Posted on

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Numinus will manage two new clinics in Montreal and Vancouver to host trials.

VANCOUVER, BC, Nov. 10, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has secured two new Canadian psychedelic clinics that will host the Canadian sites of the MAPS Public Benefit Corporation (MAPS PBC) study “A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX).”

In addition to managing the two new clinics, which are fully compliant with Health Canada regulations and ready to provide MDMA-assisted therapy as part of the trial, Numinus will host the Montreal and Vancouver sites in MAPPUSX, which will continue to study the safety and efficacy of MDMA in treating severe PTSD, under the leadership of MAPS PBC as study organizer. Numinus will also financially support costs relating to therapists who deliver the therapeutic intervention in Numinus clinics during the trial.

“We are honored to host the Canadian sites of the MAPPUSX trial as we continue to examine the important findings around MDMA-assisted therapy for PTSD,” said Dr. Joe Flanders, VP, Psychology, Numinus and therapist for the Montreal site of the trial. “Our clinical and research teams are well positioned to implement MAPS’ research and, ultimately, to work with MAPS on the translation of research findings into mainstream clinical practice. We are excited about this study in both BC and Quebec and look forward to how the MAPPUSX study supports expanded collaboration in the future.”

To date, 25 Numinus-affiliated therapists have gone through MAPS’ training program for delivery of MDMA-assisted therapy and a number of these therapists will have roles in the trial. The trial will be open to eligible participants who were previously enrolled in the placebo arm of the parent study (MAPP1) or who were not able to receive treatment due to COVID-19 restrictions.

“We are happy to work with a trusted ally to quickly complete the extension trial at the Canadian sites” said Rick Doblin, Ph.D. the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). “As we get closer to our goal of making MDMA-assisted therapy a reality, it is critical that we work with clinics who will advance making this treatment widely accessible in real-world settings.”

To accomplish this next step in the MAPPUSX study, Numinus has assumed the leases of two new clinics, the Vancouver and Montreal psychedelic-assisted psychotherapy clinics that were previously used to conduct MAPS PBC’s earlier study “A multi-site phase 3 study of MDMA-assisted psychotherapy for PTSD (MAPP1).” In that trial, 88% of participants experienced a clinically meaningful reduction in symptoms and 67% no longer qualified for a PTSD diagnosis. The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be an effective treatment for severe, chronic PTSD

Payton Nyquvest, CEO, Numinus, added, “We are thrilled that our two new locations, which are purpose-developed for psychedelic-assisted therapy, regulatorily compliant and leading in industry standards, can be used to help advance this crucial work on psychedelic medicine. We look forward to deepening our collaboration with MAPS while expanding the resources and solutions available to those suffering from PTSD.”

Securing the Canadian sites will further allow Numinus to expand its clinical activities in Quebec and BC, including its ketamine-assisted psychotherapy program, which is available in both provinces.

NOTE
The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by Health Canada or the U.S. Food and Drug Administration (FDA), does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future Health Canada or FDA approval or availability of MDMA-assisted therapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from projections.

About Numinus
Numinus Wellness (TSXV: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

About MAPS
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since its founding, MAPS has raised over $130 million for psychedelic and marijuana research and education and has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator. Learn more at maps.org

ABOUT MAPS PUBLIC BENEFIT CORPORATION (MAPS PBC)
MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics while prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit organization. Learn more at www.mapspublicbenefit.org

Forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are “forward-looking statements”. Forward-looking statements can be identified by the use of words such as “expects”, “does not expect”, “is expected”, “intends”, “anticipates”, “does not anticipate”, “believes” or variations of these words, expressions or statements, that certain actions, events or results “may”, “could”, “would”, “might” or “will be” taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate and expand the Company’s facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal and provincial legalization, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company’s limited operating and profitability track record; dependence on management; the Company’s need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the continued impact of the COVID-19 pandemic; and the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company’s efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE Numinus Wellness Inc.

For further information: May Lee, Communications Manager, Numinus, may.lee@numinus.com; Betty Aldworth, Interim Communications Director, MAPS, maps.org/mediarequest or media@maps.org; For investor inquiries: Jamie Kokoska, VP, Investor Relations, Numinus, jamie.kokoska@numinus.com

Posted on

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021

DENVER, Nov. 10, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that Dr. Rakesh Jetly, Chief Medical Officer of Mydecine, will be participating in a panel entitled, “The State of Care and the Case for Psychedelic Therapy” on Wednesday, November 10, 2021 at 7:30 p.m. on the eve of Veterans Day also known as Remembrance Day in Canada.

Hosted by Reconsider and Horizons PBC, the first of their events specifically for the veterans community, will take place live in NYC at Judson Memorial Church and will be available virtually worldwide. The Veterans + Families Forum explores the potential of therapies that use MDMA, psilocybin, ibogaine, and ayahuasca to transform the lives of the veterans and their families that struggle with mental health challenges following their service.

Dr. Jetly, Chief Medical Officer at Mydecine, stated, “It is an honor to participate in this Horizons event that is especially dedicated to raising awareness and advocating for our efforts to bring today’s most transformative therapies to veterans suffering from mental health issues. In “The State of Care and the Case for Psychedelic Therapy” panel, I will speak about our responsibilities to veterans and families, as it truly is our duty to provide them with the most advanced and effective therapies. Today, that treatment lies within the power of psychedelics.” It’s extremely encouraging to see these treatments gain acceptance in the marketplace and support from people such as Mike Ellis.”

Mike Ellis, Associate Minister of Mental Health and Addictions Alberta, recently spoke out about psychedelic-assisted psychotherapies highlighting the benefits they will bring to veterans calling them, “legitimate therapies”.

You can register for the event here.

About Mydecine Innovations Group
Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative first-and-second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug development infrastructure. Mydecine Innovations Group was founded in 2020 on the guiding principle that there is a significant unmet need and lack of Innovations in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction, and other mental health disorders. Mydecine Innovations Group’s business model combines clinical trials and data outcome, technology, scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way we view mental health disorders. Mydecine Innovations Group’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. Mydecine Innovations Group is headquartered in Denver, Colorado, USA with international offices in Leiden, Netherlands.

Learn more at: https://www.mydecine.com and follow us on Twitter and LinkedIn.

For more information, please contact:

Media Contacts
Anne Donohoe / Nick Opich
KCSA Strategic Communications
myco@kcsa.com
1-212-896-1265 / 1-212-896-1206

Investor Contacts
Charles Lee, Investor Relations
corp@mydecineinc.com
1-720-277-9879

Allison Soss / Erika Kay
KCSA Strategic Communications
myco@kcsa.com
1-212-896-1267

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com

For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.

This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

Source: Mydecine Innovations Group Inc.

Released November 10, 2021